Search

Your search keyword '"Russo Rossi AV"' showing total 5 results
Start Over Author "Russo Rossi AV"
5 results on '"Russo Rossi AV"'

1. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Author

Luigiana Luciano, Giorgina Specchia, Elisabetta Abruzzese, Nicola Sgherza, Francesco Albano, Fabio Stagno, Patrizia Pregno, Francesco Cavazzini, Antonella Russo Rossi, Gianantonio Rosti, Massimo Breccia, Giuseppe Visani, Mario Annunziata, Mario Tiribelli, Antonella Gozzini, Fausto Castagnetti, Carmen Fava, Bruno Martino, Giuliana Alimena, Pellegrino Musto, Russo Rossi AV., Breccia M., Abruzzese E., Castagnetti F., Luciano L., Gozzini A., Annunziata M., Martino B., Stagno F., Cavazzini F., Tiribelli M., Visani G., Pregno P., Musto P., Fava C., Sgherza N., Albano F., Rosti G., Alimena G., and Specchia G.

Subjects
Oncology, Male, NILOTINIB, Dasatinib, Pharmacology, THERAPY, Tyrosine-kinase inhibitor, Cytogenetic Response, hemic and lymphatic diseases, 80 and over, Treatment Failure, Chronic, IMATINIB-RESISTANT, BCR-ABL, Aged, 80 and over, Leukemia, CHRONIC MYELOGENOUS LEUKEMIA, Myeloid leukemia, Hematology, Articles, Middle Aged, Treatment Outcome, Female, Tyrosine kinase, medicine.drug, third line treatment, Adult, medicine.medical_specialty, medicine.drug_class, Last follow up, MESYLATE, NO, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, 2ND, Protein Kinase Inhibitors, CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL, IMATINIB-RESISTANT, DOMAIN MUTATIONS, MESYLATE, RESPONSES, EFFICACY, THERAPY, 2ND, Aged, business.industry, Disease progression, DOMAIN MUTATIONS, EFFICACY, Pyrimidines, Thiazoles, Nilotinib, BCR-ABL Positive, business, CHRONIC MYELOID LEUKEMIA (CML), RESPONSES, Myelogenous
Abstract

There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative tyrosine kinase inhibitor therapy. Thirty-four patients failed to respond to nilotinib and were started on dasatinib as third-line tyrosine kinase inhibitor therapy while 48 patients were switched to nilotinib after dasatinib failure. Overall, we obtained a cytogenetic response in 32 of 82 patients and major molecular response in 13 patients; disease progression occurred in 12 patients. At last follow up, 70 patients (85.4%) were alive with a median overall survival of 46 months. Our results show that third-line tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients after failure of two prior sequential tyrosine kinase inhibitors may induce a response that, in some instances, could prolong overall survival and affect event-free survival.

Published
2013

4. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.

Author

Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, Sica S, Sorà F, Lunghi F, Ciceri F, Galimberti S, Baratè C, Bonifacio M, Scaffidi L, Castagnetti F, Gugliotta G, Albano F, Russo Rossi AV, Stagno F, di Raimondo F, D'Adda M, di Bona E, Abruzzese E, Binotto G, Sancetta R, Salvucci M, Capodanno I, Girasoli M, Coluzzi S, Attolico I, Musolino C, Calistri E, Annunziata M, Bocchia M, Stella S, Serra A, Errichiello S, Saglio G, Pane F, Vigneri P, Mignone F, Laginestra MA, Pileri SA, Percesepe A, Tenti E, Rosti G, Baccarani M, Cavo M, and Martinelli G

Subjects
Adult, Aged, Aged, 80 and over, Drug Resistance, Neoplasm, Female, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Mutation, Mutation Rate, Prospective Studies, Fusion Proteins, bcr-abl genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Protein Kinase Inhibitors therapeutic use
Abstract

In chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitors (TKIs) may select for drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is considered the gold standard for BCR-ABL1 KD mutation screening, next-generation sequencing (NGS) has recently been assessed in retrospective studies. We conducted a prospective, multicenter study (NEXT-in-CML) to assess the frequency and clinical relevance of low-level mutations and the feasibility, cost, and turnaround times of NGS-based BCR-ABL1 mutation screening in a routine setting. A series of 236 consecutive CML patients with failure (n = 124) or warning (n = 112) response to TKI therapy were analyzed in parallel by SS and NGS in 1 of 4 reference laboratories. Fifty-one patients (22 failure, 29 warning) who were negative for mutations by SS had low-level mutations detectable by NGS. Moreover, 29 (27 failure, 2 warning) of 60 patients who were positive for mutations by SS showed additional low-level mutations. Thus, mutations undetectable by SS were identified in 80 out of 236 patients (34%), of whom 42 (18% of the total) had low-level mutations somehow relevant for clinical decision making. Prospective monitoring of mutation kinetics demonstrated that TKI-resistant low-level mutations are invariably selected if the patients are not switched to another TKI or if they are switched to a inappropriate TKI or TKI dose. The NEXT-in-CML study provides for the first time robust demonstration of the clinical relevance of low-level mutations, supporting the incorporation of NGS-based BCR-ABL1 KD mutation screening results in the clinical decision algorithms., (© 2020 by The American Society of Hematology.)

Published
2020
Full Text
View/download PDF

5. Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia.

Author

Sgherza N, Russo Rossi AV, Colonna P, Carluccio P, Delia M, and Specchia G

Subjects
Aged, Brugada Syndrome diagnosis, Brugada Syndrome therapy, Electrocardiography, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Male, Treatment Outcome, Antineoplastic Agents therapeutic use, Brugada Syndrome complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Protein Kinase Inhibitors therapeutic use
Abstract

The treatment and prognosis of chronic myeloid leukemia have dramatically changed since the introduction of tyrosine kinase inhibitors, but although several clinical trials have examined their safety with respect to heart function, no data are yet available about the use of these drugs in patients with Brugada syndrome. We report a case of Brugada syndrome diagnosed during tyrosine kinase inhibitor therapy in a 69-year-old Caucasian male with meningioma and chronic myeloid leukemia. This case report highlights the importance of an integrated approach among hematologists and cardiologists to ensure appropriate treatment with tyrosine kinase inhibitors in patients affected by chronic myeloid leukemia who also suffer from Brugada syndrome.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results